Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Lymphoid 1

Conditions

Leukemia 3Hematologic Neoplasms 3Multiple Myeloma 2Melanoma 2Lymphoma, Non-Hodgkin 2Breast Neoplasms 2Urinary Bladder Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Unresectable Pancreatic Carcinoma 1Triple Negative Breast Neoplasms 1Sarcoma, Kaposi 1Respiratory Tract Infections 1Respiratory Distress Syndrome 1Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pneumonia 1Pancreatic Neoplasms 1Neoplasms 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Multi-centric Castleman's Disease 1Lymphoma, Mantle-Cell 1Lymphoma 1Lymphohistiocytosis, Hemophagocytic 1Lung Neoplasms 1Leukemia, Myeloid, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1Immune-related Adverse Events 1

Interventions

tocilizumab 1Zidovudine 1Valganciclovir 1Rituximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Castleman Disease × tocilizumab × Clear all
NCT01441063 2020-10-27

Tocilizumab for KSHV-Associated Multicentric Castleman Disease

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
8 enrolled 18 charts
LymphoidSarcoma

Multi-centric Castleman's Disease, Acquired Immunodeficiency Syndrome, Castleman Disease, Sarcoma, Kaposi

Data powered by HemOnc (CC BY 4.0) Colophon âš¡